Peer-reviewedCC BY-NC-ND 4.0eClinicalMedicine
Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trial
Related
- Real-World Effects of Pemafibrate Extended-Release in Patients with Hypertriglyceridemia: A 12-Month Retrospective Study
- Histological and molecular responses to pemafibrate in MASLD with hypertriglyceridemia: the CLARITY study
- Reduction in Rheumatoid Factor and Matrix Metalloproteinase-3 With Successful Glucocorticoid Withdrawal After Initiation of Pemafibrate in a Patient With Rheumatoid Arthritis and Hypertriglyceridemia: A Case Report.
- Parasympathetic dysfunction assessed by deep-breathing CVR-R is associated with early discontinuation of oral semaglutide in type 2 diabetes: A multicenter retrospective study.
- Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort
BibTeX
@article{iwaki2026dosedependent,
title = {{Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trial}},
author = {Michihiro Iwaki and Hiroshi Tobita and Yuya Seko and Kazuhito Kawata and Kento Imajo and Koki Nagai and Takaomi Kessoku and Eiji Sakai and Yoshinobu Nakada and Satoshi Koyama and Takeo Kurihashi and Wataru Yoshioka and Shuzo Yunotani and Toshikazu Kohira and Kano Takahashi and Midori Yamamoto and Yuko Ishimaru and Noriko Oza and Yuki Yamaguchi and Shinji Iwane and Takeshi Chida and Fujito Kageyama and Yuzo Sasada and Masahiro Matsushita and Akimitsu Tadauchi and Gou Murohisa and Shuichi Sato and Kazuhisa Maeda and Koichiro Furuta and Ryuta Shigefuku and Masahiro Koseki and Takaaki Sugihara and Nobuharu Tamaki and Motoh Iwasa and Takumi Kawaguchi and Tomohisa Takagi and Miwa Kawanaka and Atsushi Kawaguchi and Atsushi Nakajima and Masato Yoneda and Hirokazu Takahashi},
journal = {eClinicalMedicine},
year = {2026},
month = oct,
doi = {10.1016/j.eclinm.2026.104226},
url = {https://linkinghub.elsevier.com/retrieve/pii/S2589537026004797},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trial
AU - Michihiro Iwaki
AU - Hiroshi Tobita
AU - Yuya Seko
AU - Kazuhito Kawata
AU - Kento Imajo
AU - Koki Nagai
AU - Takaomi Kessoku
AU - Eiji Sakai
AU - Yoshinobu Nakada
AU - Satoshi Koyama
AU - Takeo Kurihashi
AU - Wataru Yoshioka
AU - Shuzo Yunotani
AU - Toshikazu Kohira
AU - Kano Takahashi
AU - Midori Yamamoto
AU - Yuko Ishimaru
AU - Noriko Oza
AU - Yuki Yamaguchi
AU - Shinji Iwane
AU - Takeshi Chida
AU - Fujito Kageyama
AU - Yuzo Sasada
AU - Masahiro Matsushita
AU - Akimitsu Tadauchi
AU - Gou Murohisa
AU - Shuichi Sato
AU - Kazuhisa Maeda
AU - Koichiro Furuta
AU - Ryuta Shigefuku
AU - Masahiro Koseki
AU - Takaaki Sugihara
AU - Nobuharu Tamaki
AU - Motoh Iwasa
AU - Takumi Kawaguchi
AU - Tomohisa Takagi
AU - Miwa Kawanaka
AU - Atsushi Kawaguchi
AU - Atsushi Nakajima
AU - Masato Yoneda
AU - Hirokazu Takahashi
PY - 2026
DA - 2026/10/01
JO - eClinicalMedicine
DO - 10.1016/j.eclinm.2026.104226
UR - https://linkinghub.elsevier.com/retrieve/pii/S2589537026004797
SN - 2589-5370
ER -